178 related articles for article (PubMed ID: 36774237)
61. Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.
Dilworth JT; Kraniak JM; Wojtkowiak JW; Gibbs RA; Borch RF; Tainsky MA; Reiners JJ; Mattingly RR
Biochem Pharmacol; 2006 Nov; 72(11):1485-92. PubMed ID: 16797490
[TBL] [Abstract][Full Text] [Related]
62. NF1, Neurofibromin and Gene Therapy: Prospects of Next-Generation Therapy.
Cui XW; Ren JY; Gu YH; Li QF; Wang ZC
Curr Gene Ther; 2020; 20(2):100-108. PubMed ID: 32767931
[TBL] [Abstract][Full Text] [Related]
63. Neurofibromatosis type 1 (NF1): diagnosis and management.
Ferner RE; Gutmann DH
Handb Clin Neurol; 2013; 115():939-55. PubMed ID: 23931823
[TBL] [Abstract][Full Text] [Related]
64. [Gene therapy strategies and prospects for neurofibromatosis type 1].
Zheng T; Zhu B; Wang Z; Li Q
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2024 Jan; 38(1):1-8. PubMed ID: 38225833
[TBL] [Abstract][Full Text] [Related]
65. The Arg1038Gly missense variant in the NF1 gene causes a mild phenotype without neurofibromas.
Trevisson E; Morbidoni V; Forzan M; Daolio C; Fumini V; Parrozzani R; Cassina M; Midena E; Salviati L; Clementi M
Mol Genet Genomic Med; 2019 May; 7(5):e616. PubMed ID: 30843352
[TBL] [Abstract][Full Text] [Related]
66. Noonan syndrome and neurofibromatosis type I in a family with a novel mutation in NF1.
Nyström AM; Ekvall S; Allanson J; Edeby C; Elinder M; Holmström G; Bondeson ML; Annerén G
Clin Genet; 2009 Dec; 76(6):524-34. PubMed ID: 19845691
[TBL] [Abstract][Full Text] [Related]
67. Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).
Stewart DR; Korf BR; Nathanson KL; Stevenson DA; Yohay K
Genet Med; 2018 Jul; 20(7):671-682. PubMed ID: 30006586
[TBL] [Abstract][Full Text] [Related]
68. A novel neurofibromin (NF1) interaction with the leucine-rich pentatricopeptide repeat motif-containing protein links neurofibromatosis type 1 and the French Canadian variant of Leigh's syndrome in a common molecular complex.
Arun V; Wiley JC; Kaur H; Kaplan DR; Guha A
J Neurosci Res; 2013 Apr; 91(4):494-505. PubMed ID: 23361976
[TBL] [Abstract][Full Text] [Related]
69. A mouse embryonic stem cell model of Schwann cell differentiation for studies of the role of neurofibromatosis type 1 in Schwann cell development and tumor formation.
Roth TM; Ramamurthy P; Ebisu F; Lisak RP; Bealmear BM; Barald KF
Glia; 2007 Aug; 55(11):1123-33. PubMed ID: 17597122
[TBL] [Abstract][Full Text] [Related]
70. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
[TBL] [Abstract][Full Text] [Related]
71. Mid-aortic syndrome with renovascular hypertension and multisystem involvement in a girl with familiar neurofibromatosis von Recklinghausen type 1.
Petrak B; Bendova S; Seeman T; Klein T; Lisy J; Zatrapa T; Marikova T
Neuro Endocrinol Lett; 2007 Dec; 28(6):734-8. PubMed ID: 18063929
[TBL] [Abstract][Full Text] [Related]
72. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors.
Dasgupta B; Yi Y; Chen DY; Weber JD; Gutmann DH
Cancer Res; 2005 Apr; 65(7):2755-60. PubMed ID: 15805275
[TBL] [Abstract][Full Text] [Related]
73. Exploring the somatic NF1 mutational spectrum associated with NF1 cutaneous neurofibromas.
Thomas L; Spurlock G; Eudall C; Thomas NS; Mort M; Hamby SE; Chuzhanova N; Brems H; Legius E; Cooper DN; Upadhyaya M
Eur J Hum Genet; 2012 Apr; 20(4):411-9. PubMed ID: 22108604
[TBL] [Abstract][Full Text] [Related]
74. RAS and beyond: the many faces of the neurofibromatosis type 1 protein.
Anastasaki C; Orozco P; Gutmann DH
Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 35188187
[TBL] [Abstract][Full Text] [Related]
75. Co-occurrence of neurofibromatosis type 1 and optic nerve gliomas with autosomal dominant polycystic kidney disease type 2.
Peces R; Mena R; Martín Y; Hernández C; Peces C; Tellería D; Cuesta E; Selgas R; Lapunzina P; Nevado J
Mol Genet Genomic Med; 2020 Aug; 8(8):e1321. PubMed ID: 32533764
[TBL] [Abstract][Full Text] [Related]
76. The role of neurofibromin in N-Ras mediated AP-1 regulation in malignant peripheral nerve sheath tumors.
Kraniak JM; Sun D; Mattingly RR; Reiners JJ; Tainsky MA
Mol Cell Biochem; 2010 Nov; 344(1-2):267-76. PubMed ID: 20680410
[TBL] [Abstract][Full Text] [Related]
77. [Genetics of type 1 neurofibromatosis].
Garavelli L; Donadio A; Sigorini M; Grassi L; Banchini G
Acta Biomed Ateneo Parmense; 2000; 71(3-4):89-95. PubMed ID: 11424621
[TBL] [Abstract][Full Text] [Related]
78. Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice.
Sharma R; Wu X; Rhodes SD; Chen S; He Y; Yuan J; Li J; Yang X; Li X; Jiang L; Kim ET; Stevenson DA; Viskochil D; Xu M; Yang FC
Hum Mol Genet; 2013 Dec; 22(23):4818-28. PubMed ID: 23863460
[TBL] [Abstract][Full Text] [Related]
79. Jaffe-Campanacci syndrome, revisited: detailed clinical and molecular analyses determine whether patients have neurofibromatosis type 1, coincidental manifestations, or a distinct disorder.
Stewart DR; Brems H; Gomes AG; Ruppert SL; Callens T; Williams J; Claes K; Bober MB; Hachen R; Kaban LB; Li H; Lin A; McDonald M; Melancon S; Ortenberg J; Radtke HB; Samson I; Saul RA; Shen J; Siqveland E; Toler TL; van Maarle M; Wallace M; Williams M; Legius E; Messiaen L
Genet Med; 2014 Jun; 16(6):448-59. PubMed ID: 24232412
[TBL] [Abstract][Full Text] [Related]
80. Mechanistic insights from animal models of neurofibromatosis type 1 cognitive impairment.
Miller AH; Halloran MC
Dis Model Mech; 2022 Aug; 15(8):. PubMed ID: 36037004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
